Lisata Therapeutics CMO discusses potential for certepetide under Catalent license agreement

Apr 17, 2025

Lisata Therapeutics CMO discusses potential for certepetide under Catalent license agreement

Proactive - Interviews for investors

Information

Show: Proactive - Interviews for investors
Published: April 17, 2025
Type: audio
Language: EN
Author: Proactive
Categories: business investing news

Discover

Find new listens